Home / Guides / New weight loss drugs
Dated. Sourced. No forecasts.
New weight loss drugs 2027: what’s approved, what’s next and FDA dates
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Novo Nordisk expects an FDA decision on CagriSema in Q4 2026, and Lilly plans to submit retatrutide in Q1 2027, the companies say. Approved since December 2025: the Wegovy pill (December 22, 2025), Wegovy HD (March 19, 2026) and Foundayo (April 1, 2026).
- Last checked: November 1, 2026
- Approved since December 2025: Wegovy pill, Wegovy HD, Foundayo
- Next: CagriSema decision Q4 2026; retatrutide filing Q1 2027
$139/mo on a 12-month plan, all-inclusive, same price at every dose
Or $169/mo month to month
Compounded tirzepatide, not one of the drugs tracked here
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Lowest monthly price | $139 | $1,668 |
| 6-month | $149 | $1,788 |
| 3-month | $159 | $1,908 |
| Month to month | $169 | $2,028 |
Month to month costs $360 more over 12 months than the 12-month plan. Plans renew until you cancel. Longer plans bill the way you choose at checkout.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviewsLegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
Where things stand
| Question | Answer |
|---|---|
| What’s new since December 2025? | Three approvals: the Wegovy pill (December 22, 2025), Wegovy HD (March 19, 2026) and Foundayo (April 1, 2026) |
| What’s next at the FDA? | A decision on Novo Nordisk’s CagriSema, which Novo expects in Q4 2026 |
| What’s coming in 2027? | Lilly plans to submit retatrutide to the FDA in Q1 2027; Novo expects REDEFINE 11 results for CagriSema in the first half |
| And survodutide? | Phase 3 results, but no U.S. filing date announced |
| Can you buy the unapproved ones now? | No. Unapproved drugs can’t legally be sold, and the FDA says retatrutide and cagrilintide can’t be compounded |
| What will they cost? | No U.S. prices are announced for CagriSema, retatrutide or survodutide |
From the FDA and each company’s own announcements, as of November 1, 2026. Dates are the ones they announced; we don’t forecast.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Next: Novo expects an FDA decision on CagriSema in Q4 2026, and Lilly plans to submit retatrutide in Q1 2027.
- New since December 2025: the Wegovy pill, Wegovy HD (a 7.2 mg dose) and Foundayo, Lilly’s daily pill.
- Survodutide has phase 3 results, but no U.S. filing date has been announced.
- No prices yet: none are announced for CagriSema, retatrutide or survodutide, as of November 1, 2026.
- You can’t buy them early. The FDA says retatrutide and cagrilintide can’t be compounded, and “research” vials may be harmful.
- At NexLife: compounded tirzepatide, not one of these new drugs and not FDA-approved, is $139 a month on the 12-month plan.
The tracker
Where does each new weight loss drug stand?
As of November 1, 2026, CagriSema is filed, with an FDA decision expected in Q4 2026. Retatrutide’s filing is planned for Q1 2027. Survodutide has phase 3 results but no U.S. filing date. Foundayo, Wegovy HD and the Wegovy pill are approved. The unapproved drugs can’t legally be sold. Each row links to its source.
| Drug | Company | Kind | Status | Next FDA date or milestone | Source |
|---|---|---|---|---|---|
| CagriSemacagrilintide and semaglutide | Novo Nordisk | Weekly shot: amylin analog plus | Not approved. Filed with the FDA December 18, 2025 | FDA decision expected in Q4 2026 | Novo Nordisk, October 20, 2026 |
| Retatrutide | Eli Lilly | Weekly shot: GIP, | Not approved. Six positive phase 3 trials, the sixth reported October 28, 2026, Lilly says; can’t legally be sold | FDA submission (BLA) planned for Q1 2027. Head-to-head TRIUMPH-5 listed to end December 2026 | Lilly, September 29, 2026 and October 28, 2026; ClinicalTrials.gov |
| Survodutide | Boehringer Ingelheim | Weekly shot: glucagon plus | Not approved. Phase 3 results reported April 28, 2026 and October 1, 2026 | Heart-outcomes trial results expected later in 2026. No U.S. filing date announced | Boehringer Ingelheim, October 1, 2026 |
| Foundayoorforglipron | Eli Lilly | Daily pill: | FDA-approved April 1, 2026 | No FDA date announced. Reduced self-pay prices at 2.5 mg and 5.5 mg end December 31, 2026 | FDA, April 1, 2026; LillyDirect |
| Wegovy HDsemaglutide 7.2 mg | Novo Nordisk | Weekly shot: | FDA-approved March 19, 2026 | None announced | FDA, March 19, 2026 |
| Wegovy pillsemaglutide tablets | Novo Nordisk | Daily pill: | FDA-approved December 22, 2025 | List price falls to $675 a month on January 1, 2027; Novo says the cut doesn’t change self-pay prices | Novo Nordisk, December 22, 2025; February 24, 2026 |
Swipe the table sideways to see every column.
Last checked November 1, 2026. A drug is listed once it’s FDA-approved, filed with the FDA, or has phase 3 results its maker has published. “Next FDA date or milestone” is the next date the company or the FDA has announced, in its own words; we don’t forecast. The unapproved drugs can’t legally be sold.
More on each: retatrutide’s trials and timeline and Foundayo’s cost by dose.
Approved
Which new weight loss drugs were approved since December 2025?
Three: the Wegovy pill (December 22, 2025), Wegovy HD, a 7.2 mg dose of semaglutide (March 19, 2026), and Foundayo, Lilly’s daily pill (April 1, 2026). All are
| Medicine | FDA approval | What it is | Self-pay price a month |
|---|---|---|---|
| Foundayoorforglipron; Eli Lilly | April 1, 2026 | A daily | $149 to $299 at LillyDirect, by dose |
| Wegovy HDsemaglutide 7.2 mg; Novo Nordisk | March 19, 2026 | A higher weekly dose of Wegovy | $399 through NovoCare |
| Wegovy pillsemaglutide tablets; Novo Nordisk | December 22, 2025 | A daily | $149 to $299 through NovoCare, by dose |
Swipe the table sideways to see every column.
Approval dates from the FDA (Foundayo, Wegovy HD) and Novo Nordisk (Wegovy pill). Self-pay prices from LillyDirect and wegovy.com, checked November 1, 2026: the medication alone, with your prescriber’s visit extra. Foundayo’s 2.5 mg and 5.5 mg prices are reduced through December 31, 2026.
Pills or shots? How the two new pills compare with weekly injections:
Waiting
Which weight loss drugs are waiting for FDA approval?
For weight loss, one has a decision due: Novo Nordisk’s CagriSema. Novo filed it on December 18, 2025, and said on October 20, 2026 that it expects an FDA decision in Q4 2026. Retatrutide isn’t filed yet: Lilly plans to submit it in Q1 2027. Neither can be compounded.
| Filed | December 18, 2025, for weight management in adults with obesity, or overweight with a weight-related condition |
|---|---|
| Decision expected | In the fourth quarter of 2026, Novo Nordisk said on September 21, 2026 and again on October 20, 2026 |
| On the FDA’s approvals list? | No, as of November 1, 2026; the list was last updated October 20, 2026 |
| Can it be compounded? | No. The FDA says cagrilintide, one of its two ingredients, can’t be used in compounding |
Not filed yet: retatrutide. Lilly plans to submit it in Q1 2027, after it completes the manufacturing data the application needs, Lilly says.
Late 2026 and 2027
What’s coming in 2027?
In 2027, Lilly plans to submit retatrutide to the FDA in Q1, and Novo expects REDEFINE 11 results for CagriSema in the first half. On January 1, 2027, Wegovy’s list price falls to $675 (Wegovy price in 2027). Neither new drug has a U.S. launch date or price, as of November 1, 2026.
CagriSema: Novo expects the FDA’s decision.
Survodutide: Boehringer Ingelheim expects to present its heart-outcomes trial results.
Retatrutide: TRIUMPH-5, the head-to-head trial with tirzepatide, is listed to end. Lilly hasn’t said when it will report results.
Wegovy and the Wegovy pill: Novo’s list price falls to $675 a month. Novo says the cut doesn’t change self-pay prices.
Retatrutide: Lilly plans to submit a Biologics License Application to the FDA.
CagriSema: Novo expects results from REDEFINE 11, a longer trial of the current dose (Novo, February 23, 2026).
Not announced, as of November 1, 2026: a U.S. price or launch date for CagriSema or retatrutide, an FDA decision date for retatrutide, or a U.S. filing date for survodutide.
In trials
Which drugs are in late-stage trials?
Three have published phase 3 results, as of November 1, 2026. Retatrutide (Lilly) has six positive trials, the first reported December 11, 2025, and the sixth October 28, 2026. CagriSema (Novo) has its REDEFINE and REIMAGINE trials. Survodutide (Boehringer Ingelheim) reported SYNCHRONIZE-1 on April 28, 2026 and SYNCHRONIZE-2 on October 1, 2026. Only CagriSema is filed with the FDA.
Retatrutide (Eli Lilly)
Six positive phase 3 trials, Lilly says; the first, TRIUMPH-4, reported on December 11, 2025, and the sixth, TRANSCEND-T2D-2, head to head with Ozempic 2 mg in type 2 diabetes, on October 28, 2026. Lilly plans an FDA submission in Q1 2027. Retatrutide, explained, and how it compares: retatrutide vs. tirzepatide.
CagriSema (Novo Nordisk)
Phase 3 REDEFINE and REIMAGINE trials, including REDEFINE 4, head to head with tirzepatide (February 23, 2026). Filed with the FDA; a decision is expected in Q4 2026. CagriSema, explained.
Survodutide (Boehringer Ingelheim)
Phase 3 SYNCHRONIZE-1 (April 28, 2026) and SYNCHRONIZE-2 (October 1, 2026), published in The New England Journal of Medicine. No U.S. filing date announced.
Not on the list yet
Drugs still in earlier trials, or in phase 3 without published results, join the tracker when their makers publish results or file with the FDA.
Why no results here? Each trial enrolled different people, for different lengths and doses, so their numbers can’t be lined up fairly. Each drug’s results are on its maker’s page, linked in the tracker.
Prices
Will new weight loss drugs be cheaper than Zepbound or Wegovy?
No one can say yet: no U.S. prices are announced for CagriSema, retatrutide or survodutide, as of November 1, 2026. The newest approved ones cost less at their lowest doses. Foundayo and the Wegovy pill start at $149 a month self-pay. Zepbound’s starting dose is $299, and the Wegovy pen $349.
- $149a month self-pay: where Foundayo and the Wegovy pill startat their lowest doses
- $299a month: Zepbound’s starting dose at LillyDirect$349 for the Wegovy pen
- NoneU.S. prices announced for CagriSema, retatrutide or survodutideas of November 1, 2026
Novo’s list price falls in 2027. Its cut to $675 a month on January 1, 2027 matters most when your costs follow list price, as with high-deductible plans or coinsurance, Novo says; the cut doesn’t change its self-pay prices.
Two temporary self-pay prices end with 2026. Foundayo’s reduced 2.5 mg and 5.5 mg prices and Wegovy’s $199 first two fills run through December 31, 2026, their makers say.
Compounded?
Can you get any of them early from a compounder or “research” seller?
No. The FDA says retatrutide and cagrilintide, one of CagriSema’s two ingredients, can’t be used in compounding under federal law (updated October 1, 2026). The unapproved drugs can’t legally be sold, and “research” vials are of unknown quality and may be harmful, the FDA says. Anything sold online as one of them is unapproved.
“Retatrutide and cagrilintide cannot be used in compounding under federal law.”
- The FDA says retatrutide and cagrilintide aren’t components of any FDA-approved drug.
- Unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide have been sold illegally, labeled “for research purposes” or “not for human consumption,” the FDA says. It urges consumers not to buy them: they’re of unknown quality and may be harmful.
- Lilly says retatrutide “cannot be legally sold or marketed for human use.” Novo says CagriSema “is not approved for use in the United States.”
- Anything sold online as retatrutide, CagriSema, cagrilintide or survodutide is an unapproved product or a research chemical.
NexLife doesn’t offer any of them. More on why “research use” vials are risky: research peptides vs. prescribed
Available now
What can you take now?
An FDA-approved medicine by prescription, or compounded tirzepatide or semaglutide. Zepbound is $299 to $449 a month at LillyDirect, the Wegovy pen $349 and the new pills $149 to $299 (checked November 1, 2026); Zepbound’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide and semaglutide aren’t FDA-approved and aren’t any of the new drugs on this page.
| Option | FDA-approved? | Self-pay price a month |
|---|---|---|
| Zepbound (tirzepatide)weekly shot; LillyDirect | Yes | $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg with a refill within 45 days ($499 to $699 if not) |
| Wegovy pen (semaglutide)weekly shot; NovoCare | Yes | $349; $399 for Wegovy HD 7.2 mg |
| Foundayo or the Wegovy pilldaily pills | Yes | $149 to $299 by dose |
| Compounded tirzepatide at NexLifeweekly shot | No | $139 on the 12-month plan, or $169 month to month, at every dose |
| Compounded semaglutide at NexLifeweekly shot | No | $119 on the 12-month plan, or $139 month to month, at every dose |
Swipe the table sideways to see every column.
Makers’ self-pay prices checked November 1, 2026; NexLife’s are its own. Compounded tirzepatide and semaglutide are prepared by state-licensed 503A pharmacies for one patient’s prescription; they aren’t FDA-approved and aren’t any of the new drugs on this page.
At NexLife, the price is the same at every dose, with no membership fee, and a licensed provider decides if treatment is right for you.
Two medications.
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Keep your price.
Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
New weight loss drugs: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
What new weight loss drugs are coming in 2027?
Novo Nordisk expects an FDA decision on CagriSema in Q4 2026, and Lilly plans to submit retatrutide in Q1 2027, the companies say. Neither is FDA-approved, and neither can be compounded or legally sold. No launch dates or U.S. prices are announced.
What is the newest weight loss drug?
Foundayo (orforglipron), Lilly’s daily
What weight loss drugs were approved in 2026?
Foundayo, Lilly’s daily
Is retatrutide approved?
No. Lilly plans to submit it to the FDA in the first quarter of 2027, and says it “cannot be legally sold or marketed for human use.” It has six positive phase 3 trials, Lilly says, the sixth reported October 28, 2026. The FDA says retatrutide can’t be used in compounding.
Is there a new GLP-1 pill?
Yes, two are FDA-approved for weight loss: the Wegovy pill (December 22, 2025) and Foundayo (April 1, 2026). Both are daily
Will new weight loss drugs be cheaper?
No one can say yet: no U.S. prices are announced for CagriSema, retatrutide or survodutide (as of November 1, 2026). The new pills cost less at their lowest doses: Foundayo and the Wegovy pill start at $149 a month self-pay, against $299 for Zepbound’s starting dose. Foundayo’s 2.5 mg and 5.5 mg prices are reduced through December 31, 2026.
Can I get CagriSema or retatrutide from a compounding pharmacy?
No. The FDA says retatrutide and cagrilintide, one of CagriSema’s two ingredients, can’t be used in compounding under federal law. Neither is a component of any FDA-approved drug. Anything sold online as retatrutide or CagriSema is an unapproved product or a research chemical, and “research” vials may be harmful, the FDA says.
Is survodutide approved?
No. Boehringer Ingelheim has reported phase 3 results (April 28, 2026 and October 1, 2026) but hasn’t announced a U.S. filing date. It expects heart-outcomes trial results later in 2026. Survodutide is a weekly shot that acts on glucagon and
Is this list up to date?
It was last checked on November 1, 2026, against each company’s and the FDA’s own pages, and every row links to its source. A drug joins the tracker once it’s FDA-approved, filed with the FDA, or has phase 3 results its maker has published. We list only dates the companies or the FDA have announced.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and checked this page
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Every row checked against its company’s or the FDA’s page on November 1, 2026 (REIMAGINE 5 and TRIUMPH-5 on October 25, 2026).
- How we checked. Every date here comes from the company’s own announcement or the FDA, read on November 1, 2026 (REIMAGINE 5 and TRIUMPH-5 on October 25, 2026): Novo Nordisk’s, Lilly’s and Boehringer Ingelheim’s news releases, the FDA’s approvals list and press releases, the trial registries and the makers’ self-pay price pages. A drug is listed once it’s approved, filed or has published phase 3 results. We use each company’s own timing words and don’t forecast.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
Want to start with something available now?
Start with a 3-minute online check. A licensed provider decides if compounded tirzepatide is right for you: $139 a month on the 12-month plan, or $169 month to month, at every dose.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, or by secure video where your state requires a live visit. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- FDA: Novel drug approvals for 2026 (updated October 20, 2026). Checked November 1, 2026.
- FDA: Approval of Foundayo (orforglipron), the first new molecular entity under the national priority voucher program (April 1, 2026). Read November 1, 2026.
- FDA: Approval of higher-dose semaglutide, Wegovy HD (March 19, 2026). Read November 1, 2026.
- Novo Nordisk: FDA approves the Wegovy pill (December 22, 2025). Read November 1, 2026.
- Novo Nordisk: Files for FDA approval of CagriSema (December 18, 2025). Read November 1, 2026.
- Novo Nordisk: REDEFINE 4 results and FDA timing, company announcement (February 23, 2026), SEC Form 6-K. Read November 1, 2026.
- Novo Nordisk: REIMAGINE 5 results and FDA timing (September 21, 2026). Read October 25, 2026.
- Novo Nordisk: CagriSema post hoc analyses and FDA timing (October 20, 2026). Read November 1, 2026.
- Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read November 1, 2026.
- Eli Lilly: Retatrutide in TRIUMPH-4, its first successful phase 3 trial (December 11, 2025). Read November 1, 2026.
- Eli Lilly: Retatrutide TRIUMPH-1 results (May 21, 2026). Read November 1, 2026.
- Eli Lilly: Retatrutide TRIUMPH-2 and TRIUMPH-3 results, and the planned BLA (July 23, 2026). Read November 1, 2026.
- Eli Lilly: Retatrutide TRIUMPH-2 in The Lancet (September 29, 2026). Read November 1, 2026.
- Eli Lilly: Retatrutide vs. Ozempic 2 mg in TRANSCEND-T2D-2, its sixth positive phase 3 trial (October 28, 2026). Read November 1, 2026.
- Eli Lilly clinical trials: TRIUMPH-5, retatrutide compared with tirzepatide. Checked October 25, 2026.
- ClinicalTrials.gov: NCT06662383 (TRIUMPH-5). Checked October 25, 2026.
- Boehringer Ingelheim: Survodutide SYNCHRONIZE-1 results (April 28, 2026). Read November 1, 2026.
- Boehringer Ingelheim: Survodutide SYNCHRONIZE-2 results (October 1, 2026). Read November 1, 2026.
- FDA: Concerns with unapproved
GLP-1 drugs used for weight loss (updated October 1, 2026). Read November 1, 2026. - LillyDirect: Foundayo self-pay prices. Checked November 1, 2026.
- LillyDirect: Zepbound self-pay prices. Checked November 1, 2026.
- Novo Nordisk: What to pay for Wegovy. Checked November 1, 2026.
- NexLife: pricing, every plan.